ProCE Banner Activity

A Look Ahead to SABCS 2021

Conference Coverage
Clinical Thought
Experts highlight key data to help you prepare for what to expect at SABCS 2021.

Released: December 06, 2021

Expiration: December 05, 2022

Share

Faculty

Sara M. Tolaney

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

Novartis Pharmaceuticals Corporation

Sanofi Genzyme

Seagen Inc.

Faculty Disclosure

Primary Author

Sara M. Tolaney, MD, MPH

Chief, Division of Breast Oncology
Associate Director, Susan F. Smith Center for Women’s Cancers
Senior Physician, Dana-Farber Cancer Institute
Associate Professor of Medicine, Harvard Medical School
Boston, Massachusetts

Sara Tolaney, MD, MPH, has disclosed that she has received funds for research support (paid to her institution) from AstraZeneca, Bristol-Myers Squibb, Cyclacel, Eisai, Exelixis, Genentech, Immunomedics/Gilead, Lilly, Merck, NanoString, Nektar, Novartis, Odonate, Pfizer, Sanofi, and Seattle Genetics and has received consulting fees from 4D Pharma, AstraZeneca, Athenex, Bristol-Myers Squibb, Celldex, Certara, Chugai, CytomX, Daiichi Sankyo, Eisai, Ellipses Pharma, G1 Therapeutics, Genentech, Immunomedics/Gilead, Kyowa Kirin, Lilly, Mersana, NanoString, Nektar, Novartis, Odonate, OncoPep, OncoSec, Pfizer, Puma, Sanofi, Samsung Bioepsis, Seattle Genetics, and Silverback Therapeutics.